FOLH1 and prostate cancer: The first report of 177Lu-PSMA-617 therapy use in prostate cancer brain metastases came from Wei et al., in which they report significant regression of cerebral lesions following 177Lu-PSMA-617 treatment plus local radiotherapy in two patients [63].